Loading...
XSHE
300357
Market cap1.84bUSD
Jul 31, Last price  
25.35CNY
1D
-0.74%
1Q
29.07%
Jan 2017
-27.61%
IPO
-51.63%
Name

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
42.79
P/S
15.65
EPS
0.59
Div Yield, %
0.73%
Shrs. gr., 5y
—
Rev. gr., 5y
11.12%
Revenues
848m
-5.34%
37,407,15959,327,652103,176,299147,517,280193,609,754239,511,105267,105,585312,085,773385,576,841500,744,692639,352,853636,208,242807,691,606896,016,141848,190,443
Net income
310m
-11.06%
10,513,19318,405,87937,264,72953,773,77270,564,34999,554,760117,820,024129,200,974186,103,945232,884,097298,296,581278,447,284337,991,284348,773,471310,184,878
CFO
388m
+7.78%
12,628,50014,537,87119,149,70341,166,42658,303,54083,703,086114,820,239122,772,455159,134,139206,452,525232,925,579256,221,705360,575,120360,279,064388,318,565
Dividend
Jul 04, 20240.185 CNY/sh

Profile

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. It also offers skin care and stem cells series. The company is headquartered in Huzhou, China.
URL
https://www.wolwobiotech.com/
IPO date
Jan 21, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
848,190
-5.34%
896,016
10.94%
Cost of revenue
468,945
464,683
Unusual Expense (Income)
NOPBT
379,246
431,333
NOPBT Margin
44.71%
48.14%
Operating Taxes
50,433
63,022
Tax Rate
13.30%
14.61%
NOPAT
328,812
368,311
Net income
310,185
-11.06%
348,773
3.19%
Dividends
(104,717)
(105,240)
Dividend yield
0.69%
0.36%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
34,392
3,980
Long-term debt
42,512
24,565
Deferred revenue
27,428
Other long-term liabilities
59,961
28,219
Net debt
(1,168,687)
(1,107,197)
Cash flow
Cash from operating activities
388,319
360,279
CAPEX
(209,159)
Cash from investing activities
(112,333)
Cash from financing activities
(109,195)
FCF
158,212
201,149
Balance
Cash
1,288,764
1,135,742
Long term investments
(43,174)
Excess cash
1,203,181
1,090,941
Stockholders' equity
2,175,512
1,898,921
Invested Capital
1,216,134
977,769
ROIC
29.98%
41.77%
ROCE
15.67%
20.85%
EV
Common stock shares outstanding
523,607
523,584
Price
29.00
-47.37%
55.10
-3.84%
Market cap
15,184,608
-47.37%
28,849,478
-3.84%
EV
14,134,528
27,789,770
EBITDA
417,702
457,413
EV/EBITDA
33.84
60.75
Interest
1,477
444
Interest/NOPBT
0.39%
0.10%